deltatrials
Unknown PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT04942067

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

A Phase Ib/II Open-Label Study of APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma and Immunoglobin Light Chain Amyloidosis

Sponsor: Ascentage Pharma Group Inc.

Conditions Amyloidosis Multiple Myeloma
Interventions APG-2575 + DRd APG-2575+ Pd
Updated 8 times since 2021 Last updated: Oct 23, 2023 Started: Dec 23, 2021 Primary completion: Sep 1, 2024 Completion: Dec 1, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04942067, this PHASE1/PHASE2 trial focuses on Amyloidosis and Multiple Myeloma and remains ongoing. Sponsored by Ascentage Pharma Group Inc., it has been updated 8 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshotRecruiting~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshotRecruiting~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshotRecruiting~Apr 2022 – ~Nov 2023 · 19 months · monthly snapshotRecruiting~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Dec 2025 · 15 months · monthly snapshotRecruiting~Dec 2025 – present · 8 months · monthly snapshotUnknown

Change History

8 versions recorded

  1. Dec 2025 — Present [monthly]

    Unknown PHASE1/PHASE2

    Status: Recruiting → Unknown

  2. Sep 2024 — Dec 2025 [monthly]

    Recruiting PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Nov 2023 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  5. Apr 2022 — Nov 2023 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 3 earlier versions

  1. Feb 2022 — Apr 2022 [monthly]

    Recruiting PHASE1_PHASE2

  2. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE1_PHASE2

  3. Sep 2021 — Jan 2022 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ascentage Pharma Group Inc.
Data source: Ascentage Pharma Group Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations